Abstract Details

Title BMD Phenotypes from [quot]DMD[quot] Mutations: Molecular Mechanisms of Phenotypic Amelioration of Mutations in the [italic]DMD[/italic] Gene

Topic Muscle Disease/Neuromuscular Junction

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Kevin M. Flanigan, MD, FAAN (Nationwide CHildrens Hospital)	Dr. Flanigan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apic Bio. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AavantiBio. Dr. Flanigan has stock in 4D Molecular Therapeutics. The institution of Dr. Flanigan has received research support from Abeona Therapeutics. The institution of Dr. Flanigan has received research support from Sarepta Therapeutics. The institution of Dr. Flanigan has received research support from Astellas Therapeutics. Dr. Flanigan has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
	No disclosure on file
Masaki Kobayashi	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��